Skip to main content

A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease

Ziel

Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population. There is currently no specific, defined treatment for HFpEF, beyond control of risk factors. Activation of cardiac and vascular Beta3-adrenergic receptors (B3AR) represents a new concept and a novel target for structural cardiac disease. B3AR expression and coupling were demonstrated in human myocardium and vasculature. In pre-clinical models with expression of the human receptor, its activation attenuates myocardial remodelling, i.e. decreases hypertrophy and fibrosis in response to neurohormonal or hemodynamic stress. Mirabegron is a new agonist of B3AR available for human use, that was recently introduced for a non-cardiovascular indication (overactive bladder disease). The primary objective of the project is to design and implement a multi-centric, prospective, randomized, placebo-controlled clinical trial testing the additional beneficial effect of mirabegron, versus placebo over 12 months on top of standard treatment of patients carrying structural cardiac disease without overt heart failure (stage B of AHA classification); the co-primary end-point will be the quantitative change in myocardial hypertrophy measured by cardiac MRI; and in diastolic ventricular function, measured by Doppler echocardiography (E/E’); in addition, exercise tolerance (peak VO2) will be measured as well as circulating biomarkers reflecting both myocardial remodeling and function. In addition, we will test the effect of mirabegron on beige/brown fat activation and metabolism. Our proposal therefore combines a major conceptual advance and repurposing of an original drug to validate pre-clinical discoveries in the context of a major health problem.

Aufforderung zur Vorschlagseinreichung

H2020-PHC-2014-two-stage
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

RIA - Research and Innovation action
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordinator

UNIVERSITE CATHOLIQUE DE LOUVAIN
Adresse
Place De L Universite 1
1348 Louvain La Neuve
Belgien
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 819 545,51

Beteiligte (11)

UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU
Polen
EU-Beitrag
€ 480 615
Adresse
Ul Pasteura 1
50 367 Wroclaw
Aktivitätstyp
Higher or Secondary Education Establishments
Associação para Investigação e Desenvolvimento da Faculdade de Medicina
Portugal
EU-Beitrag
€ 279 823,72
Adresse
Av. Prof. Egas Moniz
1649-028 Lisbon
Aktivitätstyp
Higher or Secondary Education Establishments
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU-Beitrag
€ 607 468,75
Adresse
Wellington Square University Offices
OX1 2JD Oxford
Aktivitätstyp
Higher or Secondary Education Establishments
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Frankreich
EU-Beitrag
€ 250 562,50
Adresse
Allee De L'ile Gloriette 5
44093 Nantes
Aktivitätstyp
Higher or Secondary Education Establishments
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Deutschland
EU-Beitrag
€ 332 125
Adresse
Robert-koch-strasse 40
37075 Goettingen
Aktivitätstyp
Higher or Secondary Education Establishments
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Deutschland
EU-Beitrag
€ 426 410
Adresse
Chariteplatz 1
10117 Berlin
Aktivitätstyp
Higher or Secondary Education Establishments
AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
Italien
EU-Beitrag
€ 298 243,75
Adresse
Piazza Oms 1
24127 Bergamo
Aktivitätstyp
Other
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Greece
EU-Beitrag
€ 300 000
Adresse
6 Christou Lada Str
10561 Athina
Aktivitätstyp
Higher or Secondary Education Establishments
UNIVERSITAET LEIPZIG
Deutschland
EU-Beitrag
€ 1 082 718,75
Adresse
Ritterstrasse 26
04109 Leipzig
Aktivitätstyp
Higher or Secondary Education Establishments
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
Frankreich
EU-Beitrag
€ 306 625
Adresse
5 Rue Watt
75013 Paris
Aktivitätstyp
Research Organisations
SOCIETE EUROPEENNE DE CARDIOLOGIE
Frankreich
EU-Beitrag
€ 240 975
Adresse
Route Des Colles 2035
06903 Biot Sophia Antipolis
Aktivitätstyp
Other